Personalis Reports 44% Revenue Decline in Q3 2025, Net Loss Improves

Personalis, Inc. reported a significant decline in its financial performance for the third quarter of 2025, with total revenue of $14.5 million, down 44% from $25.7 million in the same period last year. The decrease was attributed to a $4.6 million drop in revenue from Natera, a $4.2 million decline in population sequencing revenue, and a $2.5 million reduction in revenue from pharmaceutical tests and services. For the nine months ending September 30, 2025, revenue totaled $52.3 million, a decrease of 23% compared to $67.8 million for the same period in 2024. The company reported a net loss of $21.7 million for the quarter, an improvement from a net loss of $39.1 million in the prior year.

In terms of operational metrics, Personalis delivered 4,388 clinical tests during the third quarter, marking a 26% sequential increase from the previous quarter and a 364% year-over-year growth. The company has been focusing on expanding its clinical offerings, particularly through its NeXT Personal platform, which is gaining traction among physicians for cancer monitoring. Additionally, Personalis submitted a dossier for Medicare coverage for lung cancer, with three pending indications, and launched a prospective breast cancer utility study in collaboration with Yale Cancer Center.

The company has also made strategic moves to enhance its market position. In November 2023, Personalis entered into a Commercialization and Reference Laboratory Agreement with Tempus AI, Inc. to market its NeXT Personal Dx test. This partnership has been expanded to include additional indications, such as colorectal cancer, and is expected to leverage Tempus' larger sales force to drive growth in clinical diagnostics. As of September 30, 2025, Personalis had cash and cash equivalents of $50 million and short-term investments of $100.5 million, providing a solid financial foundation for ongoing operations.

Despite the challenges, Personalis remains optimistic about its future. The company is focused on increasing sales to existing customers and expanding its customer base, particularly in the pharmaceutical sector. It is also investing in product development and marketing efforts to support its clinical diagnostic offerings. The management anticipates that the current cash reserves, along with expected cash flow from operations, will be sufficient to meet its capital and operating needs for at least the next 12 months. However, the company acknowledges that it may need to seek additional financing if market conditions do not improve or if operational challenges persist.